NCT04612790

Who might be able to join this trial:

• You are 18 years of age or older
• You have been diagnosed with bullous pemphigoid (a blistering skin condition), confirmed through skin biopsy, immune staining of the skin, and a blood test
• Your bullous pemphigoid symptoms are active and scored at a certain level of severity at both your screening and randomisation visits (confirm with trial site)
• Your doctor considers you a suitable candidate for steroid tablet treatment
• You are able to complete health questionnaires on a tablet or handheld device (exceptions may be made if you have a condition affecting your hands, fingers, or vision — confirm with trial site)
• You are male or female
• If you are a woman who could become pregnant, you must have a negative pregnancy test at screening and agree to use a highly effective form of contraception throughout the study and for 12 weeks after your last dose (accepted methods include hormonal contraception, an IUD, tubal ligation, abstinence, or a vasectomised partner)
• If you are a woman who cannot become pregnant (due to surgical sterilisation or menopause), you may still be eligible

Who may not be able to join:

• You have a less common or unusual form of bullous pemphigoid (such as mucous membrane involvement, drug-induced bullous pemphigoid, or certain other related conditions)
• You have another serious or unstable health condition that, in the doctor's opinion, could affect your safety or the study results (such as heart, liver, kidney, or psychiatric conditions)
• You have had cancer in the past 5 years — although some exceptions apply, such as certain fully treated skin cancers or cervical cancer in remission for at least 12 months (confirm with trial site)
• You have ever had a severe allergic reaction (anaphylaxis) to a biologic medicine or vaccine
• You have had a parasitic worm infection in the past 24 weeks that has not been successfully treated
• You have significant abnormal results from physical checks, blood tests, or heart tests during screening that concern the study doctor
• You currently have active liver disease (note: stable, chronic hepatitis B or C may be acceptable — confirm with trial site)
• You have liver enzyme levels (ALT or AST) that are 3 or more times above the normal range
• You have a known immune deficiency disorder, or you test positive for HIV
• You have taken certain immune-suppressing medicines (such as methotrexate, cyclosporine, or azathioprine) within approximately the past 4 weeks or longer
• You have received immunoglobulin or blood products within the past 30 days
• You have received a biologic medicine (marketed or experimental) within the past 4 months or longer (some exceptions may apply — confirm with trial site)
• You have a known allergy to any ingredient in the study medicine
• You have received a live vaccine within 30 days before joining the study
• You have previously been treated with benralizumab (also known as FASENRA or MEDI-563)
• You have recently changed or started allergen immunotherapy (allergy shots) within the past 30 days
• You have a major planned surgery scheduled during the study period
• You have already taken part in this study before
• You are currently enrolled in another clinical trial involving an experimental medicine or device
• You are involved in planning or running this study
• You are currently pregnant, breastfeeding, or lactating (for women only)
• You are unable to complete health questionnaires due to a cognitive condition such as dementia

Important: Always verify eligibility with the trial site directly before applying.